Sera Prognostics (SERA) Stock Price, News & Analysis

Company Overview

Sera Prognostics, Inc. is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test. The company has secured relevant regulatory clearances and reimbursement pathways, and continues to explore additional clinical applications for its proteomic platform. Collaborative efforts with academic institutions and health systems support ongoing studies aimed at demonstrating the test’s utility in diverse patient populations.

Headquartered in Salt Lake City, Utah, Sera Prognostics is led by President and Chief Executive Officer Zachary Carr, who brings experience in commercializing diagnostic technologies. Under his leadership, the company has built a multidisciplinary team of professionals in molecular diagnostics, clinical operations, regulatory affairs, and market access. Sera Prognostics remains dedicated to advancing maternal–fetal health and expanding its footprint through partnerships with healthcare organizations and research sponsors.

Key Stats

• Today's Range: $1.77 to $1.85
• 50-Day Range: $1.59 to $2.30
• 52-Week Range: $1.56 to $3.95
• Volume: 12,190 shs
• Average Volume: 45,991 shs
• Market Capitalization: $70.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.50
• Consensus Rating: Moderate Buy

Sera Prognostics Stock Analysis - MarketRank™

Sera Prognostics scored higher than 78% of companies evaluated by MarketBeat, and ranked 149th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Sera Prognostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Sera Prognostics has a consensus price target of $5.50, representing about 203.9% upside from its current price of $1.81.

Amount of Analyst Coverage

Sera Prognostics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Sera Prognostics are expected to grow in the coming year, from ($0.58) to ($0.51) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sera Prognostics is -2.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sera Prognostics is -2.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sera Prognostics has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.76% of the float of Sera Prognostics has been sold short.

Short Interest Ratio / Days to Cover

Sera Prognostics has a short interest ratio ("days to cover") of 5.24.

Change versus previous month

Short interest in Sera Prognostics has recently decreased by 10.75%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sera Prognostics does not currently pay a dividend.

Dividend Growth

Sera Prognostics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.63

News Sentiment

Sera Prognostics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Sera Prognostics this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Sera Prognostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $57,840.00 in company stock.

Percentage Held by Insiders

11.30% of the stock of Sera Prognostics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

54.64% of the stock of Sera Prognostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 6/29/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:SERA
• CIK: 1534969
• Web: www.seraprognostics.com
• Phone: 801-990-0520
• Fax: N/A
• Employees: 120
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Sera Prognostics: $5.50
• High Price Target: $6.00
• Low Price Target: $5.00
• Potential Upside/Downside: +203.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$31.93 million
• Net Margins: -56,385.97%
• Pretax Margin: -56,385.96%
• Return on Equity: -41.02%
• Return on Assets: -30.95%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.12
• Quick Ratio: 2.12

Sales & Book Value

• Annual Sales: $80 thousand
• Price / Sales: 886.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.94 per share
• Price / Book: 0.93

Miscellaneous

• Outstanding Shares: 39,160,000
• Free Float: 34,734,000
• Market Cap: $70.88 million
• Optionable: Optionable
• Beta: 0.94